Donald G Grosset
Overview
Explore the profile of Donald G Grosset including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan M, Iwaki H, Bandres-Ciga S, Sosero Y, Shoai M, Brockmann K, et al.
medRxiv
. 2025 Feb;
PMID: 39974079
Polygenic risk scores (PRS) in Parkinson's disease (PD) are associated with disease risk. Recently, pathway-specific PRS have been created to take advantage of annotations inking variants to biological pathways or...
2.
Wu L, Real R, Martinez-Carrasco A, Chia R, Lawton M, Shoai M, et al.
Brain Commun
. 2024 Jul;
6(4):fcae190.
PMID: 38978726
Up to 80% of Parkinson's disease patients develop dementia, but time to dementia varies widely from motor symptom onset. Dementia with Lewy bodies presents with clinical features similar to Parkinson's...
3.
Gandhi S, Nodehi A, Lawton M, Grosset K, Marshall V, Ben-Shlomo Y, et al.
Mov Disord Clin Pract
. 2024 Jun;
11(9):1113-1124.
PMID: 38898616
Background: Dopaminergic responsiveness is a defining feature of Parkinson's disease (PD). However, there is limited information on how this evolves over time. Objectives: To examine serial dopaminergic responses, if there...
4.
Tan M, Lawton M, Pollard M, Brown E, Real R, Carrasco A, et al.
NPJ Parkinsons Dis
. 2024 Jun;
10(1):113.
PMID: 38849413
There are 90 independent genome-wide significant genetic risk variants for Parkinson's disease (PD) but currently only five nominated loci for PD progression. The biology of PD progression is likely to...
5.
Gandhi S, Zerenner T, Nodehi A, Lawton M, Marshall V, Al-Hajraf F, et al.
Mov Disord Clin Pract
. 2024 Apr;
11(6):686-697.
PMID: 38587023
Background: Motor complications are well recognized in Parkinson's disease (PD), but their reported prevalence varies and functional impact has not been well studied. Objectives: To quantify the presence, severity, impact...
6.
Wu L, Real R, Martinez A, Chia R, Lawton M, Shoai M, et al.
medRxiv
. 2023 Nov;
PMID: 37987016
Up to 80% of Parkinson's disease patients develop dementia, but time to dementia varies widely from motor symptom onset. Dementia with Lewy bodies presents with clinical features similar to Parkinson's...
7.
Martinez-Carrasco A, Real R, Lawton M, Iwaki H, Tan M, Wu L, et al.
NPJ Parkinsons Dis
. 2023 Aug;
9(1):128.
PMID: 37652906
The genetic basis of levodopa-induced-dyskinesia (LiD) is poorly understood, and there have been few well-powered genome-wide studies. We performed a genome-wide survival meta-analyses to study the effect of genetic variation...
8.
Martinez-Carrasco A, Real R, Lawton M, Iwaki H, Tan M, Wu L, et al.
medRxiv
. 2023 Jul;
PMID: 37425912
Importance: Forty percent of Parkinson's disease patients develop levodopa-induced-dyskinesia (LiD) within 4 years of starting levodopa. The genetic basis of LiD remains poorly understood, and there have been few well...
9.
Lawton M, Ben-Shlomo Y, Athauda D, Malek N, Grosset D
Front Aging Neurosci
. 2023 Jul;
15:1223636.
PMID: 37396660
No abstract available.
10.
Venuto C, Smith G, Herbst K, Zielinski R, Yung N, Grosset D, et al.
Mov Disord
. 2023 Jun;
38(10):1774-1785.
PMID: 37363815
Background: In Parkinson's disease (PD), gait and balance is impaired, relatively resistant to available treatment and associated with falls and disability. Predictive models of ambulatory progression could enhance understanding of...